ClotCare: Blood Clots, Stroke, Heart Attack
Monday, October 7, 2024
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Aspirin for Primary Prevention of Strokes and Heart Attacks

Henry I. Bussey, Pharm.D., FCCP, FAHA
April, 2009

The March 17, 2009 issue of Annals of Internal Medicine contains three important articles for those weighing the risks and benefits of taking aspirin for the prevention of heart attacks and stroke. The three articles are summarized briefly below:

First of Three articles:
Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events : An update of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2009; 150(6):405-410.

This publication reviews the literature and reaches the conclusion that aspirin reduces the risk for myocardial infarction in men and the risk for ischemic stroke in women; but the authors also conclude that aspirin increases the risk of serious bleeding. Closer scrutiny also indicates that aspirin increases the risk of hemorrhagic stroke in men by about 69%, but the increase in hemorrhagic stroke in women was only 29%, which was not statistically significant.

Second of Three articles:
U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task For Recommendation Statement. Annals of Internal Medicine. 2009; 150(6): 396-404.

The summary recommendations of this report are that:

  • Men 45 to 79 years of age be "encouraged" to take aspirin "when the potential benefit of a reduction in myocardial infarction outweighs the potential harm of an increase in gastrointestinal hemorrhage."


  • Women age 55 to 79 years be "encouraged" to use of aspirin when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage.


  • Evidence is insufficient to make recommendations for men or women over 80 years of age.


  • Use of aspirin not be encouraged in women younger than 55 years and men younger than 45 years.

Although the summary of the recommendations does not address the increased risk of hemorrhagic stroke related to aspirin, the body of the article contains a nice table that allows one to exam the number needed to help (based on 10-year risk of a cardiovascular event) vs. the number needed to harm (based on gastrointestinal hemorrhage and hemorrhagic stroke risk due to aspirin). The risk of developing cardiac disease can be quickly calculated online at http://healthlink.mcw.edu/article/923521437.html. Because the risk of harm from major bleeding increases with age and the potential for benefit with aspirin increases with higher 10-year cardiovascular risk, the point at which the risk and benefit are similar can be approximated (see table).

Age and cardiovascular risks at which the benefits and risks approximate each other (increasing age leads to increased risk of bleeding while increased 10-year cardiovascular risk leads to increased benefit of aspirin).

Men Women
Age groups % 10-yr Card. risk Age groups % 10-yr Card. risk
45 - 59 yrs > 4 55 - 59 yrs > 3
60 - 69 yrs > 9 60 - 69 > 8
70 - 79 yrs > 12 70 - 79 > 11

For any age group, a 10-year card. risk profile greater than the figure listed in the table would favor aspirin therapy. Adapted from USPSTF report. Ann Intern Med 2009; 150:396-404.

Third of Three articles:
Mehta SR. Aspirin for prevention and treatment of cardiovascular disease. Annals of Internal Medicine 2009; 150(6):414-416

This editorial reviews the recommendations for aspirin use described and provides further insight into the analysis. For instance, the author questions the wisdom of making recommendations based on gender when conclusions are based on post-hoc analysis and a limited number of studies that included women. Also examined is the issue of personal preference in weighing different potential end points. For example, would a patient prefer to have a myocardial infarction (MI) or a gastrointestinal bleed? If the bleed is favored, how many bleeds would one be willing to trade for one MI. Alternatively, a hemorrhagic stroke may be more devasting than an MI or an ischemic stroke.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-860-0487
Send comments to webmaster@clotcare.org.
Monday, October 7, 2024